Quantcast
Home > Quotes > DNLI

Denali Therapeutics Inc. Common Stock (DNLI) Quote & Summary Data

DNLI 
$20.48
*  
0.78
3.96%
Get DNLI Alerts
*Delayed - data as of Dec. 18, 2018  -  Find a broker to begin trading DNLI now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
25
Today's High / Low
$ 20.63 / $ 19.71
Share Volume
540,575
50 Day Avg. Daily Volume
354,207
Previous Close
$ 19.70
52 Week High / Low
$ 25.789 / $ 12.32
Market Cap
1,944,721,244
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.97
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.44

Intraday Chart

Shares Traded

Share Volume:
540,575
50 Day Avg. Daily Volume:
354,207

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.97

Trading Range

The current last sale of $20.48 is 66.23% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 20.63 $ 25.789
 Low: $ 19.71 $ 12.32

Company Description (as filed with the SEC)

Neurodegeneration represents one of the most significant unmet medical needs of our time, with few effective therapeutic options available for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis ("ALS"), and other neurodegenerative diseases. The burden of these diseases to patients and society is massive. We believe the time is right to make a strong and ambitious effort to defeat neurodegeneration. We believe that we can succeed in a field that has seen limited success in the past, because of our team of experienced and passionately dedicated scientists and drug developers, our focused scientific strategy, and our proprietary blood-brain barrier ("BBB"), platform delivery technology. We are developing a broad portfolio of targeted therapeutic candidates for neurodegenerative diseases and currently have two programs in Phase 1 clinical development.  ... More ...  


Risk Grade

Where does DNLI fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 19.85
Open Date:
Dec. 18, 2018
Close Price:
$ 20.48
Close Date:
Dec. 18, 2018

Consensus Recommendation

Analyst Info